OncoSec Medical

OncoSec Medical

Employees:
50
Market Cap:
$21.99 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-25.29 million
NASDAQ:
ONCS
OncoSec Medical
Employees:
50
Market Cap:
$21.99 million
Revenue:
$0.0
5 Year Trend:
0.0%
Net Income:
$-25.29 million
NASDAQ:
ONCS

Jul 27, 8:41 PM

Anti-PD-1 refractory melanoma is a major unmet medical need. There are currently no available treatment options for patients with metastatic melanoma who have failed anti-PD-1 therapy. OncoSecs immunotherapy is in a position to be the first available treatment to this population.

Jul 24, 9:22 PM

ImmunoPulse IL-12 works by altering the immunogenicity of the tumor, driving the frequency of tumor-infiltrating lymphocytes (TILs) to transform a cold to hot tumor. These tumors often lead to increased PDL1 expression on the tumor, providing the substrate to maximize the utility of anti-PD-1 therapies.

Jul 12, 9:01 PM

At OncoSec, were proud to currently be the only company in the anti-PD1 non-responder patient population with Fast Track and Orphan Drug Designation for the treatment of unresectable metastatic melanoma. We are hard at work to bring innovative treatments into the hands of patients who need it.

Jul 4, 5:07 PM

Have a happy and safe Fourth of July!